Display options
Cite
Anne M, Sammartino D, Barginear MF, et al. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther. 2013;6:1613-24doi: 10.2147/OTT.S30773.
Anne, M., Sammartino, D., Barginear, M. F., & Budman, D. (2013). Profile of panobinostat and its potential for treatment in solid tumors: an update. OncoTargets and therapy, 61613-24. https://doi.org/10.2147/OTT.S30773
Anne, Madhurima, et al. "Profile of panobinostat and its potential for treatment in solid tumors: an update." OncoTargets and therapy vol. 6 (2013): 1613-24. doi: https://doi.org/10.2147/OTT.S30773
Anne M, Sammartino D, Barginear MF, Budman D. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther. 2013 Nov 15;6:1613-24. doi: 10.2147/OTT.S30773. eCollection 2013. PMID: 24265556; PMCID: PMC3833618.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2013 Nov 15;6:1613-24. doi: 10.2147/OTT.S30773. eCollection 2013.

Profile of panobinostat and its potential for treatment in solid tumors: an update.

OncoTargets and therapy

Madhurima Anne, Daniel Sammartino, Myra F Barginear, Daniel Budman

Affiliations

  1. Monter Cancer Center, Hofstra North Shore-LIJ School of Medicine, Lake Success, NY, USA.

PMID: 24265556 PMCID: PMC3833618 DOI: 10.2147/OTT.S30773

Abstract

The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer. Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both intravenous and oral formulations across multiple tumor types. Comparable to the other HDACs, panobinostat leads to hyperacetylation of histones and other intracellular proteins, allowing for the expression of otherwise repressed genes, leading to inhibition of cellular proliferation and induction of apoptosis in malignant cells. Panobinostat, analogous to other HDAC inhibitors, also induces apoptosis by directly activating cellular death receptor pathways. Preclinical data suggests that panobinostat has inhibitory activity at nanomolar concentrations and appears to be the most potent clinically available HDAC inhibitor. Here we review the current status of panobinostat and discuss its role in the treatment of solid tumors.

Keywords: LBH589; histone deacetylase inhibitor; panobinostat; solid tumors

References

  1. Invest New Drugs. 2010 Dec;28 Suppl 1:S3-20 - PubMed
  2. Oncotarget. 2012 Nov;3(11):1416-27 - PubMed
  3. BMC Cancer. 2012 Sep 03;12:386 - PubMed
  4. Cancer Chemother Pharmacol. 2010 May;66(1):181-9 - PubMed
  5. J Cancer. 2012;3:158-65 - PubMed
  6. Cancer Chemother Pharmacol. 2012 Oct;70(4):513-22 - PubMed
  7. Invest New Drugs. 2011 Dec;29(6):1224-9 - PubMed
  8. Mol Cancer Ther. 2012 Apr;11(4):973-83 - PubMed
  9. Nat Rev Cancer. 2006 Jan;6(1):38-51 - PubMed
  10. Crit Rev Oncol Hematol. 2008 Oct;68(1):29-36 - PubMed
  11. J Cell Biochem. 2009 Jul 1;107(4):600-8 - PubMed
  12. J Biol Chem. 2005 Jul 22;280(29):26729-34 - PubMed
  13. Cell. 2012 Jul 6;150(1):12-27 - PubMed
  14. Invest New Drugs. 2012 Jun;30(3):1096-106 - PubMed
  15. Leukemia. 2013 Aug;27(8):1628-36 - PubMed
  16. Anticancer Res. 2012 Mar;32(3):1027-31 - PubMed
  17. J Hepatol. 2012 Jun;56(6):1343-50 - PubMed
  18. Cancer Chemother Pharmacol. 2011 Sep;68(3):805-13 - PubMed
  19. Mol Cancer Ther. 2009 Aug;8(8):2221-31 - PubMed
  20. Transl Oncol. 2013 Apr;6(2):143-57 - PubMed
  21. J Clin Endocrinol Metab. 2012 Jul;97(7):E1150-9 - PubMed
  22. Mol Oncol. 2007 Jun;1(1):19-25 - PubMed
  23. Clin Cancer Res. 2009 Jun 15;15(12):4066-76 - PubMed
  24. Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6532-7 - PubMed
  25. Cancer Lett. 2009 Aug 8;280(2):233-41 - PubMed
  26. Cancer Lett. 2013 Feb 1;329(1):17-26 - PubMed
  27. Br J Cancer. 2012 Jan 3;106(1):107-15 - PubMed
  28. Gastroenterology. 2012 Jul;143(1):99-109.e10 - PubMed
  29. Anticancer Drugs. 2012 Mar;23(3):272-9 - PubMed
  30. PLoS One. 2010 Apr 28;5(4):e10376 - PubMed
  31. Curr Opin Genet Dev. 1999 Feb;9(1):40-8 - PubMed
  32. Cancer Chemother Pharmacol. 2012 Feb;69(2):555-62 - PubMed
  33. J Neurooncol. 2012 Mar;107(1):133-8 - PubMed
  34. Clin Cancer Res. 2009 Jun 15;15(12):3958-69 - PubMed
  35. Cell Oncol. 2010 Jan 1;32(4):285-300 - PubMed
  36. Taiwan J Obstet Gynecol. 2011 Jun;50(2):165-71 - PubMed
  37. Cancer Invest. 2011 Aug;29(7):451-5 - PubMed
  38. BMC Med Genomics. 2009 Nov 30;2:67 - PubMed
  39. Cancer Res. 2006 Dec 1;66(23):11298-304 - PubMed
  40. J Pathol. 2009 Aug;218(4):467-77 - PubMed
  41. Breast Cancer Res. 2012 May 21;14(3):R79 - PubMed
  42. Cancer Res. 2011 May 15;71(10):3635-48 - PubMed
  43. Cancer Res. 2008 Apr 15;68(8):2557-60 - PubMed
  44. Mol Cancer Ther. 2007 Sep;6(9):2515-24 - PubMed
  45. Cell Death Differ. 2013 Oct;20(10):1306-16 - PubMed
  46. Int J Cancer. 2012 Feb 1;130(3):694-704 - PubMed
  47. Apoptosis. 2012 Dec;17(12):1300-15 - PubMed

Publication Types